← Back to patent-cliff list
[68Ga]BED003
Tier C — Watch / trade[68Ga]BED003
Blue Earth Diagnostics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：Updating
Indications (approved)：Colorectal cancer, Epithelial ovarian cancer, Gastric cancer, 小叶癌, 胰腺导管癌
Regional status
US
-
EU
Phase II
2026-06-30
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of [68Ga]BED003?
Approved indications include: Colorectal cancer, Epithelial ovarian cancer, Gastric cancer, 小叶癌, 胰腺导管癌.
When does the [68Ga]BED003 patent expire?
No public expiry year is available for [68Ga]BED003 yet; this page updates once verified.
How do I get a quote for [68Ga]BED003 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29